Hims eventual short thesis (not full fledged thesis just thoughts while im about to go to sleep): Hims financials are showing slowed growth with very little margin, high acquisition cost, and competitors such as Medvi producing similar revenue in a shorter time period while also

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin